Scaling Up Antibody-Drug Conjugate Payloads

Article

Newer, more complex targeted therapies are entering clinical development at rapid speeds, requiring facilities to increase manufacturing capacity levels in order to keep up with demands and under the strictest levels of containment.

Related Content